Best Pharma Stocks in November 2026 Based on 5-Year CAGR: Neuland Laboratories, Wockhardt and More

The pharmaceutical sector has seen various companies demonstrate impressive growth over the past 5 years. This article highlights the top 10 pharma stocks based on their 5-year compound annual growth rate (CAGR), offering a glimpse into their financial performance and market standing. 

Top 10 Pharma Stocks Based on 5-Year CAGR in November 2026 

Note: The above data is as of October 29, 2026. 

Neuland Laboratories Limited 

Neuland Laboratories Limited leads the pharmaceutical pack with an impressive 5-year CAGR of 63.11%. The company commands a market capitalization of ₹24,736.03 crore, closing at a market price of ₹19,280.  

It exhibits a premium PE ratio of 67.96 paired with a substantial PB ratio of 13.20. It demonstrates high capital efficiency with a Return on Equity (ROE) of 21.42% and ROCE of 23.11%, yielding a solid 1-year return of 25.15%. 

Wockhardt Limited 

Wockhardt Limited follows strongly on the list, securing a 5-year CAGR of 37.34%. The firm has a market capitalization of ₹31,249.46 crore, with a close price of ₹1,922.90. The stock shows an elevated PE ratio of 146.71 and a PB ratio of 5.92.  

Its operational metrics reflect a Return on Equity of 4.29% alongside a ROCE of 6.48%, delivering a robust 1-year performance trajectory of 47.17%. 

Marksans Pharma Limited 

Marksans Pharma Limited features prominently with a 5-year CAGR of 36.70%. Its overall market capitalization stands at ₹14,290.52 crore, closing out at a price of ₹315.35. The stock offers a defensive valuation posture with a PE ratio of 34.20 and a PB ratio of 4.68.  

The firm supports healthy core fundamentals, including an ROE of 15.08% and ROCE of 17.56%, translating into a highly productive 1-year return of 71.67%. 

Strides Pharma Science Limited 

Strides Pharma Science Limited reports a sustainable 5-year CAGR of 36.18%. The company represents a market capitalization of ₹10,115.96 crore, concluding at a close price of ₹1,097.50.  

It exhibits attractive market valuation multiples with a low PE ratio of 18.19 and a PB ratio of 3.21. Its structural profitability boasts an ROE of 19.39% and ROCE of 21.66%, contributing to an excellent 1-year return of 29.02%. 

Glenmark Pharmaceuticals Limited 

Glenmark Pharmaceuticals Limited holds its position firmly, maintaining a 5-year CAGR of 35.94%. The large-cap enterprise records a total market capitalization of ₹66,012.35 crore, establishing a close price of ₹2,339.00.  

The stock tracks at a reasonable PE ratio of 48.47 and a PB ratio of 6.28. It delivers balanced capital ratios with an ROE of 14.07% and ROCE of 16.21%, recording a reliable 1-year growth rate of 26.89%. 

Laurus Labs Limited 

Laurus Labs Limited marks a spectacular showing with a 5-year CAGR of 34.19%. The massive market capitalization stands at ₹1,21,246.06 crore, maintaining a close price of ₹2,244.00.  

The stock carries a growth-oriented valuation structure with a PE ratio of 136.42 and a high PB ratio of 22.32. The underlying business maps out an ROE of 17.72% and a ROCE of 19.67%, capturing an eye-catching 1-year return expansion of 133.34%. 

Shilpa Medicare Limited 

Shilpa Medicare Limited showcases strong momentum with a 5-year CAGR of 26.25%. The business maps onto a market capitalization of ₹18,298.63 crore, locking a close price of ₹935.60. The firm operates at a PE ratio of 75.20 alongside a PB ratio of 7.06.  

Its fundamentals reveal an ROE of 9.82% and ROCE of 12.39%, driving an extraordinary, explosive 1-year return of 161.56%. 

Torrent Pharmaceuticals Limited 

Torrent Pharmaceuticals Limited remains a cornerstone entity, publishing a stable 5-year CAGR of 26.21%. The sector leader commands a massive market capitalization of ₹1,74,208.48 crore, finalizing at a close price of ₹4,580.00.  

The stock prints a PE ratio of 80.53 and a PB ratio of 9.91. It provides an institutional-grade ROE of 17.19% and ROCE of 9.24%, generating an investment return of 27.25% over the past year. 

Caplin Point Laboratories Limited 

Caplin Point Laboratories Limited advances securely with a 5-year CAGR of 23.68%. The enterprise reflects a total market capitalization of ₹18,061.14 crore, closing at a specific price point of ₹2,376.10.  

It operates with highly appealing market multiples, carrying a PE ratio of 28.17 and a PB ratio of 4.97. High efficiency shines through an ROE of 19.68% and ROCE of 22.01%, culminating in a 1-year return of 17.57%. 

Granules India Limited 

Granules India Limited closes the top tier list with a stable 5-year CAGR of 21.99%. The company represents a market capitalization of ₹22,841.22 crore, recording a close market price of ₹837.35.  

The stock exhibits a conservative PE ratio of 38.39 alongside a PB ratio of 4.49. The operating framework demonstrates consistent capital metrics with an ROE of 13.52% and ROCE of 16.09%, finalizing a sound 1-year equity return of 46.57%. 

Read More: Best Water Management Stocks in India for November 2026 Based on 5-Year CAGR! 

Conclusion 

The top 10 pharma stocks based on 5-year CAGR are spearheaded by Neuland Laboratories at 63.11%, followed by Wockhardt at 37.34%, and Marksans Pharma at 36.70%. These prominent pharmaceutical operators show highly diverse capitalization scale, valuation parameters, efficiency ratios, and short-term trailing performance records. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.